四環醫藥今日底部放量大漲43.48%,究竟發生了什麼?

這次集結令很榮幸邀請到四環醫藥的三位高管,來給各位投資者分享四環醫藥最近業務進展。
2020年10月26日,四環醫藥(0460.HK)發佈公吿,由公司獨家代理的、韓國生物製藥公司Hugel,Inc. 生產的“注射用A型肉毒毒素(Letybo100U,商品名:樂提葆)”正式獲中國國家藥品監督管理局批准上市,成為第四個獲准在中國上市的A型肉毒毒素,也是韓國同類產品中的首個。該產品於2020年年底前開始在中國內地銷售。
醫美領域市場廣闊已是產業界和資本市場共識,大A股的愛美客、華熙生物和昊海生科已經被資本抱團了很久,不知道本輪南下資金會不會錯過四環醫藥這個標的。

會議時間 | 2021年1月21日(週四)13:15-14:15
會議主題 | 四環醫藥(0460.HK)
會議嘉賓 | 孫超(市場總監)、馮鶯(銷售總監)、JuliaMiao(首席投資官)
參會資格 | 諮詢客服獲取限量免費參會資格
參會方式 | 微信掃碼聯繫格隆匯-機構客服(微信ID:glh-jg),或者對口銷售經理。

掃碼添加客服報名參會
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.